Rituximab, primarily used as a second-line biologic therapy, was used in a cost-saving and adverse-event reducing on-demand schedule in 94.6% of patients; these patients were assessed for signs of relapse and the need for another rituximab infusion at their regularly scheduled visits, and they also had the option of contacting a healthcare provider by phone if they felt that they were relapsing.
Recent studies, including the ALTERRA study, have reported that low and very low doses of rituximab are effective in treating rheumatoid arthritis (RA), and a new study that describes the real-world use of rituximab in a single center in Spain suggests that a low dose of rituximab, administered on-demand rather than at predetermined intervals, provides a good long-term treatment option for some patients.
The retrospective cohort study considered adult patients with RA who were treated with rituximab from 2005 to 2014, with a follow-up period through 2015. In total, 114 patients with 409 cycles of treatment were considered.
Rituximab, primarily used as a second-line biologic therapy, was used in a cost-saving and adverse-event reducing on-demand schedule in 94.6% of patients; these patients were assessed for signs of relapse and the need for another rituximab infusion at their regularly scheduled visits, and they also had the option of contacting a healthcare provider by phone if they felt that they were relapsing. The remaining 5.4% of patients were on a fixed 6-month dosing schedule.
The researchers report that the median number of rituximab cycles per patient was 3 (range, 1-11), and a dose of 1000 mg, versus the standard 2000 mg, was used in 31.8% of treatment cycles. Overall, 91.5% of first cycles used the recommended 2000 mg dose, but the percentage of doses that used the 1000 mg dose rose to 80% to 100% of patients with more than 6 cycles of treatment.
Overall, there was an average disease activity improvement after rituximab administration after each cycle. Duration of response could only be measured in the on-demand cycles (n = 314). The median response duration for patients with on-demand treatment was 10 months (interquartile range, 7-13).
A multivariable analysis revealed that older age (65 years or older) and higher number of rituximab cycles were significantly associated with longer response duration. When rituximab was used as a third biologic or higher, the response duration was approximately 2 months shorter than in those patients who used the drug as a first- or second-line therapy. The dose per cycle was not associated with response duration.
“Our data suggest that, after a successful first cycle of 2000 mg, retreatments with rituximab can be scheduled as cycles of 1000-mg single [infusions]…resulting in a comfortable schedule of treatment with acceptable control of disease activity in most patients,” conclude the authors.
Reference
Cañamares-Orbis I, Merino L, López J, et al. Experience with the use of rituximab for the treatment of rheumatoid arthritis in a tertiary hospital in Spain: RITAR study. [Published online July 19, 2018.] J Clin Rheumatol. doi: 10.1097/RHU.0000000000000845.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis
October 19th 2024A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.